Suven Life Sciences · NSE: SUVEN · BSE: 530239
Q2 FY22 results · Jul–Sep 2021
Suven Life Sciences reported revenue from operations of ₹1.18 crore (down 86.8% from Q2 FY21) and net loss of ₹28.30 crore for Q2 FY22 (Jul–Sep 2021), on a consolidated basis.
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1.18 | 8.98 | −86.8% | 2.01 | −41.0% |
| Other income | 0.50 | 2.28 | −77.9% | 4.56 | −89.0% |
| Total income | 1.69 | 11.26 | −85.0% | 6.56 | −74.3% |
| Profit before tax | (28.30) | (16.65) | Loss widened | (39.21) | Loss narrowed |
| Net profit for the period | (28.30) | (15.66) | Loss widened | (39.21) | Loss narrowed |
| EPS, basic (₹) | (2.22) | (1.23) | Loss widened | (3.08) | Loss narrowed |
| Net margin (%) | -2389.8 | -174.4 | -1954.5 |
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1.18 | 8.98 | −86.8% | 2.01 | −41.0% |
| Other income | 0.50 | 2.28 | −77.9% | 4.56 | −89.0% |
| Total income | 1.69 | 11.26 | −85.0% | 6.56 | −74.3% |
| Profit before tax | (10.98) | (2.89) | Loss widened | (8.49) | Loss widened |
| Net profit for the period | (10.98) | (1.90) | Loss widened | (8.49) | Loss widened |
| EPS, basic (₹) | (0.86) | (0.15) | Loss widened | (0.67) | Loss widened |
| Net margin (%) | -927.5 | -21.2 | -423.4 |
Consolidated
- Filed with BSE
- 27 Oct 2021, 12:08 IST
- Board meeting
- 25 Oct 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 27 Oct 2021, 12:08 IST
- Board meeting
- 25 Oct 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE